Centrus Energy Corp Dossier - Source-backed chat

Centrus Energy Corp

LEUNYSE

SectorEnergy

IndustryUranium

Beta (adjusted)1.23

Intrinsic Value $44.48median of 4 methods · middle span $39-$50based on filings through 30 Jun 2026

Market Price $139.11Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 68% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-68%)

Data confidence Sign in to view data confidence

Market Cap $2.8B

Enterprise Value $2.2B

Shares Outstanding 20.5M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

Last ex-dividend22 Nov 2005

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Centrus Energy Corp. (LEU) is uniquely positioned as the sole U.S.-owned uranium enrichment supplier, serving as a critical pillar in the restoration of domestic nuclear fuel supply chains. The company is transitioning from a broker-trader model to a primary domestic enricher, supported by a massive $3.9 billion backlog (including $2.4 billion in contingent commitments) and historic federal funding opportunities. With the global shift toward nuclear energy, rising demand for High-Assay, Low-Enriched Uranium (HALEU) for advanced small modular reactors, and strategic partnerships with Fluor, Palantir, and Geiger Brothers, Centrus offers a high-conviction growth profile. While near-term capital intensity and geopolitical supply dependencies present risks, its fortress-like balance sheet and strategic monopoly make it a compelling long-term buy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$170.00

Mean target$257.33

High · most bullish analyst$340.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$170.00

Geopolitical tensions lead to an abrupt halt of Russian LEU imports without timely waivers, disrupting the broker-trader business before domestic capacity is established. Regulatory delays or funding bottlenecks from the DOE slow down the Piketon expansion. Capital expenditures escalate beyond expectations, and execution friction with construction partners delays the commercial production timeline past 2029, leading to margin compression and share dilution from convertible note conversions.

Base CaseCentral scenario

$257.33

Matches the consensus mean

Centrus executes its 2026 operational plan, achieving its updated full-year revenue guidance of $450 million to $500 million. The company continues to secure necessary waivers for Russian imports to bridge the supply gap until domestic commercial capacity comes online in 2029. Centrifuge manufacturing scales steadily with support from public and private capital, and the $3.9 billion backlog is progressively converted. Wall Street consensus maintains a positive outlook with steady progress toward domestic enrichment independence.

Bull CaseUpside scenario

$340.00

The Department of Energy fully funds and awards the $900 million task orders for both LEU and HALEU production. Centrus successfully accelerates its centrifuge manufacturing build-out in Oak Ridge and Piketon, achieving commercial-scale production ahead of the 2029 target. Strategic partnerships with Palantir and Fluor yield cost savings exceeding the projected $300 million. Global demand for HALEU escalates rapidly due to accelerated deployments of advanced reactors (e.g., Oklo), driving high-margin contract conversions and substantial valuation multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Sole U.S.-owned uranium enrichment supplier with deployment-ready gas centrifuge technology.
Robust $3.9 billion total backlog extending to 2040, providing long-term revenue visibility.
Pioneering position in HALEU production, a critical fuel required for next-generation advanced reactors.
Fortress balance sheet with substantial cash reserves and strategic partnerships to mitigate execution risks.

Key Investment Risks

High near-term dependency on Russian uranium imports and the regulatory waiver process.
Significant capital intensity and execution risks associated with scaling up centrifuge manufacturing.
Reliance on federal funding and timely Department of Energy task order allocations.

Thesis Invalidation Triggers

Denial of critical import waivers for Russian LEU before domestic capacity is operational.
Failure to secure or a material reduction in expected DOE task order funding.
Severe delays in the commercial-scale centrifuge deployment timeline beyond 2029.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.